Abstract 879P
Background
Immune checkpoint inhibitor (ICI) pembrolizumab with or without chemotherapy is first-line (1L) treatment for most patients with unresectable, recurrent or metastatic (R/M) HNSCC. PDS0101 (Versamune® HPV) is a novel, investigational HPV16-targeted therapeutic cancer vaccine that stimulates a potent, targeted T cell attack against HPV16-positive cancers.
Methods
We conducted a single-arm phase II study evaluating PDS0101 and pembrolizumab for 1L HPV16-positive R/M HNSCC. Subjects received pembrolizumab 200 mg IV Q3W with PDS0101 1 mL SC administered concurrently during Cycles 1, 2, 3, 4, and 12 and pembrolizumab monotherapy for all other Cycles up to Cycle 35 (approx. 2 years). The primary study endpoint was confirmed BOR per RECIST 1.1. Herein we report OS and update data on safety, ORR, and PFS in ICI naïve subjects.
Results
The study has completed enrollment. Ten subjects remain on treatment and 21 subjects are in long-term survival follow up. Demographics are previously reported; of note, 60.4% CPS 1-19 and 39.6% CPS ≥20. The median OS was 30 months (95% CI 18.4, NE) and the 12-month OS rate was 80%. Eighteen subjects (34%) had confirmed response by investigator assessment (4 CR and 14 PR). In the CPS≥20 cohort, 10/21 (48%) subjects had a confirmed response. The median PFS was 6.3 months (95% CI 3.1, 14.1). In the CPS≥20 cohort, median PFS was 14.1 months. Updated safety will be presented; no new safety signals emerged and the most common TRAEs remain injection site reactions, fatigue, headache, and pruritis with only 13% of subjects experiencing Grade ≥3 TRAEs. No subject had Grade 5 TRAE.
Conclusions
Enrollment is complete. Pembrolizumab plus PDS0101 shows excellent tolerability. Survival data are favorable compared to historic expectations, especially when PD-L1 levels of accrued subjects are considered. These results support further evaluation in a randomized phase III study.
Clinical trial identification
NCT04260126.
Editorial acknowledgement
Legal entity responsible for the study
PDS Biotechnology Corporation.
Funding
PDS Biotechnology Corporation.
Disclosure
J. Weiss: Financial Interests, Personal, Speaker, Consultant, Advisor: PDS Biotechnology. J. Kaczmar: Financial Interests, Personal, Advisory Board: PDS Biosciences, EMD serono; Financial Interests, Institutional, Local PI: EMD, PDS, Bicara, Merck, Replimmune; Financial Interests, Personal, Coordinating PI, research funding for IIT at MUSC: Signatera. K.J. Harrington: Financial Interests, Institutional, Steering Committee Member: GSK, AZ, MSD, Merck-Serono; Financial Interests, Institutional, Advisory Board: AZ, MSD, Merck Serono; Financial Interests, Institutional, Funding: AZ; Financial Interests, Institutional, Local PI: AZ, MSD; Financial Interests, Institutional, Invited Speaker: MSD, Merck-Serono; Financial Interests, Institutional, Research Funding: Merck-Serono; Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck-Serono. R. Mehra: Financial Interests, Personal, Speaker, Consultant, Advisor: Coherus Biosciences, Janssen Oncology, Merck KGaA; Financial Interests, Institutional, Research Funding: AZ, Merck; Non-Financial Interests, Personal, Advisory Role: AZ. F. Worden: Financial Interests, Personal, Advisory Board: PDS Biotechnology. H. Kang: Financial Interests, Personal, Other, Consultant: PIN therapeutics, Hanmi Pharmaceuticals; Financial Interests, Personal, Other, Data safety monitoring board: MitoImmune; Financial Interests, Personal, Advisory Board: HLB group, LG Chem, Coherus; Financial Interests, Institutional, Coordinating PI: Elevar therapeutics; Financial Interests, Institutional, Local PI: Eli Lilly, PDS biotechnology, Ayala, Remix Therapeutics, Merus; Financial Interests, Institutional, Trial Chair: NeoImmune Tech; Non-Financial Interests, Member: American Society of Clinical Oncology, American Association for Cancer Research, International Thyroid Oncology Group, American Thyroid Association, Society of Immunotherapy of Cancer. C. Grant: Financial Interests, Personal, Advisory Board: Roche Pharmaceuticals, BMS; Financial Interests, Personal, Advisory Role: Roche Pharmaceuticals. S. Jones, D. Schaaf: Financial Interests, Personal, Stocks/Shares: PDS Biotechnology. K. Price: Non-Financial Interests, Institutional, Advisory Role: InSitu Biologics; Financial Interests, Institutional, Speaker, Consultant, Advisor: PDS Biotechnology. All other authors have declared no conflicts of interest.
Resources from the same session
751P - Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial
Presenter: Carol Aghajanian
Session: Poster session 02
752P - Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
Presenter: Tibor Zwimpfer
Session: Poster session 02
753P - Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
Presenter: Felix Blanc-Durand
Session: Poster session 02
754P - Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
Presenter: Ronnie Shapira-Frommer
Session: Poster session 02
755P - Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer
Presenter: Maj Kamille Kjeldsen
Session: Poster session 02
756P - Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
Presenter: Junsik Park
Session: Poster session 02
757P - Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study
Presenter: Juan Cueva Banuelos
Session: Poster session 02
758P - Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients
Presenter: Emese Zsiros
Session: Poster session 02
759P - JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
Presenter: Qunxian Rao
Session: Poster session 02
760P - Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial
Presenter: Jie Tang
Session: Poster session 02